Positive Quality Intervention: FGFR Inhibitor Side Effect Management

**Description:** Fibroblast growth factor receptor (FGFR) inhibitors are a class of oral oncolytics approved for certain FGFR-altered malignancies, including bladder cancer (erdafitinib) and cholangiocarcinoma (infigratinib and pemigatinib). FGFR inhibitors come with unique adverse effect profiles and monitoring considerations. The purpose of this PQI is to provide multidisciplinary team members with key education, monitoring, and supportive care considerations for patients on these therapies.

**Background:** The FGFR family of proteins (FGFR 1-4) are transmembrane tyrosine kinase signaling proteins with several physiologic functions including cell proliferation, differentiation, embryogenesis, angiogenesis and phosphate homeostasis. FGFR mutations and fusions can drive cancer growth via increased cell proliferation and survival, angiogenesis, and resistance to anticancer agents. The first FDA-approved FGFR inhibitor, erdafitinib is a pan-FGFR inhibitor indicated for advanced or metastatic urothelial carcinoma with susceptible FGFR 2 or 3 genetic mutations and translocations after progression on at least 1 platinum-containing chemotherapy. Erdafitinib demonstrated an objective response rate of 40% in the phase II BCL2001 trial. Both pemigatinib and infigratinib inhibit FGFR 1-3 and are approved for previously treated, unresectable advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. Pemigatinib demonstrated a 36% objective response rate in the FGFR2-altered population of the phase II FIGHT-202 trial. Infigratinib yielded a 19% objective response rate patients with FGFR2 fusions in a phase II trial. All three agents were approved under the accelerated approval pathway, with final approval pending results of phase III trials. Due to the unique physiologic roles of FGFR kinases, FGFR inhibitors have unique toxicity profiles. Hyperphosphatemia is a key on-target adverse effect of the FGFR inhibitors and requires specific monitoring. Furthermore, hyperphosphatemia may predict superior outcomes – erdafitinib requires a dose increase for those who do not experience hyperphosphatemia to optimize its efficacy. Other side effects also deserve attention including ocular toxicities, dermatologic toxicities, diarrhea, and fatigue. Each of these agents also carries the risk for fetal harm due to the role of FGFR in embryonal development.

**PQI Process:** Upon receipt of an order for an FGFR inhibitor:

- Review patient’s history, including diagnosis and prior treatments
- Verify the presence of a susceptible FGFR alteration for that drug or malignancy
  - Erdafitinib: select FGFR2 fusions, FGFR3 fusions, or FGFR3 mutations
  - Pemigatinib and infigratinib: select FGFR2 fusions or other arrangements
- Assess baseline renal and hepatic function and need for any initial dose reductions (Table 1)
- Review concomitant medications for interactions, dose adjustments, or spacing as appropriate
- Evaluate pregnancy status prior to use in females of reproductive potential: counsel females and males with female partners of reproductive potential on appropriate contraception due to risk of fetal harm
- Ensure ophthalmologic exams at baseline and at appropriate intervals throughout treatment (Table 1)

**Patient Centered Activities:**

- Provide Oncology Chemotherapy Education (OCE) sheet for appropriate FGFR inhibitor to patient

---

**Important notice:** NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. *Updated 11.22.21*
● Review dosing schedule and calendar with patient
● Discuss signs and symptoms of hyperphosphatemia: muscle cramps, numbness, tingling in the mouth
● For patients on erdafitinib, discuss implementing a low-phosphate diet before the initial dose increase period (14-21 days) with a goal of less than 600 - 800 mg phosphate in a day and should also avoid medications that increase phosphate including supplements, vitamin D, and some antacids
  ○ High phosphate foods: dairy, beans, lentils, processed meats, nuts, sodas with phosphates
  ○ Low phosphate foods: fresh fruits and vegetables, rice, fish, breads, pasta
● Discuss dry eye and symptoms of ocular toxicity (central serous retinopathy/retinal pigment epithelial detachment): blurred vision, loss of vision, or other visual changes
● Provide expectations for lab monitoring when starting therapy, especially during the first 2-3 months
● Review dosing with patients as dose reductions occur to ensure proper administration
● Medications should be stored in a cool, dry place at room temperature
● FGFR inhibitors should be taken at about the same time each day *If a dose is missed, doses should not be doubled, they should be logged, and reported to the provider
● Patient assistance
  ○ Erdafitinib: https://www.balversa.com/support-resources/cost-support
  ○ Pemigatinib: https://hcp.incytecares.com/pemazyre/home.aspx
  ○ Infigratinib: https://www.truseltiq.com/hcp/forging-bridges-overview

References

Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. Updated 11.22.21
## Supplemental Information:
### Table 1. Dosing and Monitoring Guideline Summary

<table>
<thead>
<tr>
<th></th>
<th>Erdafitinib (Balversa®)&lt;sup&gt;3&lt;/sup&gt;</th>
<th>Pemigatinib (Pemazyre®)&lt;sup&gt;8&lt;/sup&gt;</th>
<th>Infgratinib (Truseltiq™)&lt;sup&gt;9&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FDA Indication</strong></td>
<td>Advanced or metastatic urothelial carcinoma with susceptible FGFR2 or 3 genetic mutations after at least 1 platinum-containing chemotherapy</td>
<td>Unresectable advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement, after previous treatment</td>
<td>Unresectable advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement, after previous treatment</td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>8 mg (2 x 4 mg tablet) PO daily. Increase dose to 9 mg (3 x 3 mg tablet) daily after 14-21 days if phosphate &lt; 5.5 mg/dL and no ocular or grade ≥ 2 toxicity. Take with or without food.</td>
<td>13.5 mg (1 x 13.5 mg tablet) PO daily for 14 consecutive days of a 21-day cycle. Take with or without food.</td>
<td>125 mg (1 x 100 mg plus 1 x 25 mg capsules) PO daily for 21 consecutive days of a 28-day cycle. Administer on an <strong>empty stomach</strong> at least 1 hour before or 2 hours after food.</td>
</tr>
<tr>
<td><strong>Dosage forms</strong></td>
<td>3 mg, 4 mg, 5 mg tablet</td>
<td>4.5 mg, 9 mg, 13.5 mg tablet</td>
<td>100 mg, 25 mg capsule</td>
</tr>
<tr>
<td><strong>Dose reductions</strong></td>
<td>8 mg → 6 mg → 5 mg → 4 mg → discontinue</td>
<td>13.5 mg → 9 mg → 4.5 mg → discontinue</td>
<td>125 mg → 100 mg → 75 mg → 50 mg → discontinue</td>
</tr>
<tr>
<td><strong>Use in organ dysfunction</strong></td>
<td>Renal impairment: No adjustment required. Hepatic impairment: No adjustment required.</td>
<td>Renal impairment: Dose reduction required for eGFR &lt; 30 mL/min/1.73m&lt;sup&gt;2&lt;/sup&gt;. Hepatic impairment: Dose reduction required for bilirubin &gt;3 times ULN.</td>
<td>Renal impairment: Dose reduction required for CrCl 30-89 mL/min, for CrCl &lt; 30mL/min specific recommendations are not established. Hepatic impairment: Dose reduction required for bilirubin or AST above ULN.</td>
</tr>
<tr>
<td><strong>Pregnancy</strong></td>
<td>Use contraception during treatment and for 1 month after last dose.</td>
<td>Use contraception during treatment and for 1 week after last dose.</td>
<td>Use contraception during treatment and for 1 month after last dose.</td>
</tr>
<tr>
<td><strong>Drug-Drug or Food-Drug interactions</strong></td>
<td>CYP3A4 and CYP2C9 inducers and inhibitors. Restrict phosphate intake to 600 to 800 mg daily during the initial dose adjustment period. Avoid vitamin D supplements, antacids, phosphate-containing enemas or laxatives, or other medications with phosphate excipients.</td>
<td>CYP3A4 inducers and inhibitors.</td>
<td>CYP3A4 inducers and inhibitors. Avoid use with PPIs. If H2RAs must be used, administer infgratinib 2 hours before or 10 hours after. Administer infgratinib 2 hours before or after mineral antacids. Take on an empty stomach due to increased absorption with food.</td>
</tr>
</tbody>
</table>
Monitoring

<table>
<thead>
<tr>
<th>Serum phosphate</th>
<th>Baseline, day 14-21, then monthly</th>
<th>As clinically necessary (monitor weekly if hyperphosphatemia develops)</th>
<th>As clinically necessary (monitor weekly for serum phosphate &gt;5.5 mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median time to onset: 20 days</td>
<td>Median time to onset: 8 days</td>
<td>Median time to onset: 8 days</td>
</tr>
<tr>
<td>Eye exams, including optical coherence tomography</td>
<td>Baseline, monthly x 4 months, then every 3 months thereafter and as clinically necessary</td>
<td>Baseline, every 2 months x 6 months, then every 3 months thereafter and as clinically necessary</td>
<td>Baseline, at 1 month, at 3 months, then every 3 months thereafter and as clinically necessary</td>
</tr>
<tr>
<td></td>
<td>Median time to onset: 50 days</td>
<td>Median time to onset: 62 days</td>
<td>Median time to onset: 26 days</td>
</tr>
<tr>
<td>Common adverse drug reactions</td>
<td>Fatigue, onycholysis, alopecia, paronychia, stomatitis, diarrhea/constipation, decreased appetite, dysgeusia, nausea</td>
<td>Alopecia, nail changes, constipation/diarrhea, dysgeusia, nausea, decreased appetite, fatigue</td>
<td>Alopecia, nail changes, abnormal eyelash growth, constipation/diarrhea, decreased appetite, dysgeusia, fatigue, epistaxis</td>
</tr>
<tr>
<td></td>
<td>Increased ALT, AST, alkaline phosphatase, creatinine, phosphate</td>
<td>Increased serum creatinine, ALT, AST, bilirubin, calcium, glucose</td>
<td>Increased phosphate, triglycerides, creatinine</td>
</tr>
<tr>
<td></td>
<td>Decreased sodium, albumin, magnesium, hemoglobin</td>
<td>Decreased albumin, sodium</td>
<td>Decreased sodium, ALT, AST, alkaline phosphatase, bilirubin</td>
</tr>
</tbody>
</table>

Table 2. Clinical Trial Summary

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>Description</th>
<th>Outcome</th>
</tr>
</thead>
</table>
| **BLC2001 Study**  | Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 alterations | Erdafitinib | Objective tumor response 40%  
Median duration of PFS 5.5 months  
Median duration of OS 13.8 months |
| **FIGHT-202 Study** | Unresectable, locally advanced, metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement | Pemigatinib | Objective tumor response 35.5%  
Median DOR 7.5 months (5.7-14.5 months) |
| **CBGJ398X2204 Study** | Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement | Infigratinib | ORR 23.1% (95% CI 15.6-32.2)  
Median DOR 5.0 months (0.9-19.1 months) |

PFS: Progression Free Survival, OS: Overall Survival, DOR: Duration of Response, ORR: Overall Response Rate